Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
The New England journal of medicine, 2018-01, Vol.378 (4), p.392-394
Ort / Verlag
United States: Massachusetts Medical Society
Erscheinungsjahr
2018
Link zum Volltext
Quelle
Alma/SFX Local Collection
Beschreibungen/Notizen
Although there has been considerable research activity in the treatment of Hodgkin’s lymphoma since advanced stages of the disease became curable with combination chemotherapy in the 1960s, the most significant advances have involved the maintenance of a particular level of antitumor efficacy while acute and late toxic side effects and their attendant mortality are reduced. These advances include the preservation of high response rates at reduced levels of toxicity with the current standard regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD); the demonstration that various forms of radiation therapy were associated with unacceptably high levels of long-term toxicity; the application . . .